Know Cancer

or
forgot password
  • cancer clinical trials in oklahoma

  • Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
    University of Oklahoma Health Sciences Center

    Trial Locations
    University of Oklahoma Health Sciences Center
    Cancer Care Associates-Yale
    Recurrent Uterine Sarcoma, Uterine Carcinosarcoma
    Registry Study for Proton Therapy Outcomes
    ProCure Proton Therapy Center
    Oklahoma City, Oklahoma 73142
    Solid Tumors
    Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
    University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104
    Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach, Recurrent Esophageal Cancer, Recurrent Gastric Cancer
    Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer
    Oklahoma University Cancer Institute
    Oklahoma City, Oklahoma 73104
    Cervical Cancer
    E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma
    Peggy & Charles Stephenson Oklahoma Cancer Ctr
    Oklahoma City, Oklahoma 73104
    Hepatocellular Carcinoma
    Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery
    Cancer Centers of Southwest Oklahoma Research

    Trial Locations
    Cancer Centers of Southwest Oklahoma Research
    Cancer Care Associates-Norman
    University of Oklahoma Health Sciences Center
    Cancer Care Associates-Mercy
    Mercy Physicians of Oklahoma-Lakeside
    Recurrent Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
    Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
    INTEGRIS Cancer Institute of Oklahoma

    Trial Locations
    INTEGRIS Cancer Institute of Oklahoma
    Natalie W Bryant Cancer Center
    Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer
    Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
    University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104
    Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
    Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
    University of Oklahoma Health Sciences Center

    Trial Locations
    University of Oklahoma Health Sciences Center
    Cancer Care Associates-Yale
    Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Cancer, Stage IVB Cervical Cancer
    BKM120 as Second-line Therapy for Advanced Endometrial Cancer
    University of Oklahoma Health Sciences Center OU Health
    Oklahoma City, Oklahoma 73104
    Advanced Endometrial Cancer
    Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors
    Univ. Oklahoma Health Science Center
    Oklahoma City, Oklahoma 73104
    Advanced Solid Malignant Tumors, Advanced Ovarian Cancer
    Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer
    Oklahoma University Cancer Institute

    Trial Locations
    Oklahoma University Cancer Institute
    Cancer Care Associates - Saint Francis Campus
    Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
    Safety Study of X-82 in Patients With Advanced Solid Tumors
    Peggy and Charles Stephens Oklahoma Cancer Center
    Oklahoma City, Oklahoma 73104
    Advanced Solid Tumors
    Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
    University of Oklahoma Health Sciences Center Dept. of Oklahoma Univ. HSC
    Oklahoma City, Oklahoma 73104
    Non-small Cell Lung Cancer
    A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine
    The Office of Johnny B. Roy, MD

    Trial Locations
    The Office of Johnny B. Roy, MD
    Lynn Health Science Institute
    Legacy Clinical Research, LLC
    Overactive Bladder
    Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant
    Oklahoma University Cancer Institute
    Oklahoma City, Oklahoma 73104
    Bacterial Infection, Mucositis, Neutropenia
    A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
    Cancer Centers of Southwest Oklahoma

    Trial Locations
    Cancer Centers of Southwest Oklahoma
    Urologic Specialists of Oklahoma
    Advanced Prostate Cancer, Prostatic Neoplasms
    E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck
    Peggy & Charles Stephenson Oklahoma Cancer Ctr
    Oklahoma City, Oklahoma 73104
    Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck
    PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
    Oklahoma University Cancer Institute
    Oklahoma City, Oklahoma 73104
    Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
    Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma
    University of Oklahoma Health Sciences Center

    Trial Locations
    University of Oklahoma Health Sciences Center
    Natalie W Bryant Cancer Center
    Recurrent Neuroblastoma
    Pilot Study of Lupron to Improve Immune Function After Allogeneic Bone Marrow Transplantation
    University of Oklahoma
    Oklahoma City, Oklahoma 73190
    Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome RAEB 1
    Reduced Intensity Conditioning Versus Myeloablative Conditioning for Acute Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)
    University of Oklahoma Medical Center
    Oklahoma City, Oklahoma 73104
    Leukemia, Myelocytic, Acute
    Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors
    Oklahoma University
    Tulsa, Oklahoma 74104
    Malignant Solid Tumour
    Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
    Research Site
    Enid, Oklahoma
    Cancer, Hematologic Malignancies, Multiple Myeloma, Oncology, Bone Metastases, Multiple Myeloma Bone Lesions
    Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery
    University of Oklahoma Health Sciences Center

    Trial Locations
    University of Oklahoma Health Sciences Center
    Natalie W Bryant Cancer Center
    Breast Cancer
    A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
    University of Oklahoma Health Science Center
    Oklahoma City, Oklahoma 73104
    Hematological Malignancies, Certain Lysosomal Storage and Peroxisomal Enzyme Deficiency Disorders, Hurler Syndrome (MPS I), Krabbe Disease (Globoid Leukodystrophy), X-linked Adrenoleukodystrophy, Primary Immunodeficiency Diseases, Bone Marrow Failure, Beta-thalassemia
    FOLFIRINOX in Patients With Inoperable Pancreatic Cancer
    University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104
    Adenocarcinoma of Pancreas
    PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma
    Natalie Warren Bryant Cancer Center at St. Francis Hospital
    Tulsa, Oklahoma 74136
    Lymphoma
    ARCHER 1009 : A Study Of PF-00299804 (Dacomitinib) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer
    Pfizer Investigational Site
    Bartlesville, Oklahoma 74006
    Non-Small Cell Lung Cancer (NSCLC)
    National Marrow Donor Program Long-Term Donor Follow-Up
    Oklahoma Blood Institute
    Oklahoma City, Oklahoma 73104-3251
    Hematologic Neoplasms
    Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
    Oklahoma University Cancer Institute

    Trial Locations
    Oklahoma University Cancer Institute
    Cancer Care Associates - Saint Francis Campus
    Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
    Long-Term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children Who Completed OTR3001
    Lynn Health Sciences Institute

    Trial Locations
    Lynn Health Sciences Institute
    The Children's Hospital at Oklahoma University Medical Center
    Pain